Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by AlloVir, Inc. AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference November 16, 2023 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir Reports Third Quarter 2023 Financial Results November 02, 2023 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir to Present at Upcoming Investor Conferences August 28, 2023 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir Reports Second Quarter 2023 Financial Results August 03, 2023 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir Announces Pricing of Public Offering of Common Stock June 21, 2023 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir Announces Proposed Public Offering of Common Stock June 21, 2023 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant Congress (ATC 2023) June 05, 2023 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir to Present at the BofA Securities 2023 Health Care Conference May 01, 2023 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023 April 26, 2023 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook February 15, 2023 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia February 15, 2023 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir to Participate in the SVB Securities Global Biopharma Conference February 01, 2023 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023 January 09, 2023 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference January 03, 2023 From AlloVir, Inc. Via Business Wire Tickers ALVR Final Data from AlloVir’s Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting November 03, 2022 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir Reports Third Quarter 2022 Financial Results November 03, 2022 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference August 31, 2022 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir Reports Second Quarter 2022 Financial Results August 04, 2022 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir Announces $126.6 Million Registered Direct Offering July 27, 2022 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients June 07, 2022 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir Reports First Quarter 2022 Financial Results May 05, 2022 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference November 15, 2021 From AlloVir, Inc. Via Business Wire Tickers ALVR FDA Grants Orphan Drug Designation (ODD) to AlloVir’s Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis October 04, 2021 From AlloVir, Inc. Via Business Wire Tickers ALVR Data Presented at IDWeek™ 2021 Demonstrate that ALVR109, AlloVir’s Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta September 29, 2021 From AlloVir, Inc. Via Business Wire Tickers ALVR AlloVir to Present at the Morgan Stanley 19th Annual Global Healthcare Conference September 07, 2021 From AlloVir, Inc. Via Business Wire Tickers ALVR Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.